Cell Signaling Technology

Product Pathways - Growth Factors/Cytokines

Human Neuregulin-1 (hNRG-1) #5218

Request pricing for multi-milligram amounts.

Source

Recombinant human NRG-1 (hNRG-1) Thr176-Lys238 (Accession #NP_001153480) was produced in E. coli cells at Cell Signaling Technology.

Molecular Characterization

Recombinant hNRG-1 does not have a Met on the amino terminus and has a calculated MW of 7,415. DTT-reduced and non-reduced protein migrate as 6 kDa polypeptides. The expected amino-terminal TSHLV of recombinant hNRG-1 was verified by amino acid sequencing.

Purity

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hNRG-1. All lots are greater than 98% pure.

Bioactivity

The bioactivity of recombinant hNRG-1 was determined in a cell proliferation assay using MCF7 cells. The ED50 of each lot is between 1-4 ng/ml.

Coomassie Gel

Coomassie Gel

The purity of recombinant hNRG-1 was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hNRG-1 and staining overnight with Coomassie Blue.

Bioactivity

Bioactivity

The proliferation of MCF7 cells treated with increasing concentrations of hNRG-1 was assessed. After a 7 day treatment with hNRG-1 cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.

Western Blotting

Western Blotting

Western blot analysis of extracts from MCF7 cells, untreated or treated with hNRG-1 for 7 minutes, using Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP® Rabbit mAb #4370 (upper) and p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb #4695 (lower).


Endotoxin

Less than 0.01 ng endotoxin/1 μg hNRG-1.

Formulation

With carrier: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl and 20 μg BSA per 1 μg hNRG-1. Carrier free: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl.

Background

NRG-1, a member of the EGF family, is involved in heart, mammary and nervous system development (1). NRG-1 is expressed by mammary epithelial, vascular endothelial and neuronal cells (2,3). At least 15 NRG-1 splice variants are known (1). These variants differ in EGF domains (α or β variants), amino-terminal splicing sites, and incorporation of exons encoding integral membrane regions (1). NRG-1 can induce or inhibit the proliferation of cells derived from breast cancer. The differences in effects of NRG-1 appear to depend on splice variation and interaction with receptor(s) (2). NRG-1 binds to ErbB3/HER3 or ErbB4/HER4. Binding induces dimerization with ErB2/HER2. The Akt, Erk1/2 and Erk5 pathways have been shown to participate in NRG-1 activated signaling (4,5). NRG-1 appears to have roles in schizophrenia and breast cancer (1,4,6).

  1. Falls, D.L. (2003) Exp Cell Res 284, 14-30.
  2. Chua, Y.L. et al. (2009) Oncogene 28, 4041-52.
  3. Kalinowski, A. et al. (2010) FASEB J, [Epub ahead of print] .
  4. Montero, J.C. et al. (2008) Clin Cancer Res 14, 3237-41.
  5. Grossmann, K.S. et al. (2009) Proc Natl Acad Sci U S A 106, 16704-9.
  6. Mei, L. and Xiong, W.C. (2008) Nat Rev Neurosci 9, 437-52.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.

Products